Atopic Dermatitis - KOL Insight

Description

Explore the evolving landscape of atopic dermatitis treatment. Insights from leading KOLs highlight the promising potential of Lilly/Almirall's Ebglyss, which is expected to rival Dupixent in efficacy and market share. Experts also discuss the cautious optimism surrounding rocatinlimab (Kyowa Kirin/Amgen), noting the need for further efficacy validation and investigation into side effects. Additionally, amlitelimab (Sanofi) shows intriguing Phase IIb data with a favourable dosing schedule, though more data is required. Gain an understanding of the new biologics and emerging therapies shaping the future of atopic dermatitis treatment.

In addition to the full report, licensed users have access to the following KOL Bulletins and special reports via the attachments area.

Key questions answered:

How is Dupixent (dupilumab; Sanofi/Regeneron) used in the treatment of atopic dermatitis, what other trials are being conducted, and how will it be prescribed in the future?
Among recently launched products, which mechanisms of action and/or products are the most promising?
Which pipeline products are the most promising, and how will they impact current players in the market?
Which clinical trials have the potential to impact prescribing trends, and how will the results affect the future treatment of atopic dermatitis?
How will the treatment landscape for atopic dermatitis evolve in the future?

Key brands covered in this report:

Dupixent (dupilumab)
Adbry/Adtralza (tralokinumab)
Ebglyss (lebrikizumab)
Olumiant (baricitinib)
Cibinqo (abrocitinib)

Rinvoq (upadacitinib)
nemolizumab
Velsipity (etrasimod)
rocatinlimab
amlitelimab

Companies Listed:

AbbVie
Amgen
Lilly
Regeneron
Sanofi
Pfizer
Almirall S.A.

Leo Pharma
Incyte
Chugai
Galderma
Maruho
Kyowa Kirin

Executive summary

Future treatment paradigm for atopic dermatitis

Research objectives

Current treatment strategies

Dupixent (dupilumab; Sanofi/Regeneron)
- Key insights summary
Adbry/Adtralza (tralokinumab; LEO Pharma)
- Key insights summary
Ebglyss (lebrikizumab; Lilly/Almirall)
- Key insights summary
Olumiant (baricitinib; Lilly/Incyte)
- Key insights summary
Cibinqo (abrocitinib; Pfizer)
- Key insights summary
Rinvoq (upadacitinib; AbbVie)
- Key insights summary

Late-stage pipeline programmes

Nemolizumab (Galderma/Chugai/Maruho)
- Key insights summary
Velsipity (etrasimod; Pfizer)
- Key insights summary
Rocatinlimab (Kyowa Kirin/Amgen)
- Key insights summary
Amlitelimab (Sanofi)
- Key insights summary

Earlier-stage developments and other factors impacting treatment

KOLs are unconvinced that dual SYK/JAK inhibition will have a place in atopic dermatitis due to safety concerns
- PD1 agonist antibody is deemed to be a risky prospect
- Most experts don't think TYK2 inhibition will work as well in atopic dermatitis
- Optimism surrounds the development of bispecific antibodies
- Biomarkers are generally seen as irrelevant
- Less frequent dosing will become increasingly important in the future

Appendix

KOL details
- US KOLs
- European KOLs